Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
MLLT1
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "MLLT1" in MCE Product Catalog:
2
2 Cited Publications
Target:
Research Areas:
SGC-iMLLT is a first-in-class chemical probe and a potent, selective inhibitor of MLLT1/3-histone interactions with an IC50 of 0.26 μM. SGC-iMLLT shows high binding activity towards MLLT1 YEATS domain (YD) and MLLT3 YD (AF9/YEATS3) with Kds of 0.129 and 0.077 μM, respectively [1].
Cat. No.: HY-160287
CAS No.: 2561471-13-2
Target:
Research Areas:
NVS MLLT-1 (compound 3), a chemical probe, is a potent and selective MLLT1 inhibitor with Kd values of 0.18 μM, 0.24 μM, and 0.22 μM for wild-type, T1 mutants, and T3 mutants, respectively [1] .
Target:
Research Areas:
PFI-6 is a selective MLLT1 and MLLT3 YEATS domain probe with IC50 values of 0.14 μM and 0.16 μM, respectively. PFI-6 is applicable for cancer research [1].
Cat. No.: HY-RS08493
Target:
Research Areas:
MLLT1 Human Pre-designed siRNA Set A contains three designed siRNAs for MLLT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-181834
CAS No.: 3111054-37-3
Target:
Research Areas:
PROTAC MLLT1 Degrader-1 is a PROTAC degrader targeting MLLT1. PROTAC MLLT1 Degrader-1 inhibits AML cell proliferation and viability, suppresses tumor growth in human AML xenograft models, and can block the oncogene transcriptional program. PROTAC MLLT1 Degrader-1 can be used for the research of MLL-rearranged acute myeloid leukemia (AML) [1].
Cat. No.: HY-176821
CAS No.: 2650530-01-9
Target:
Research Areas:
PFI-6N is a negative control compound of PFI-6 (HY-155412). PFI-6N is completely inactive against YEATS domain (MLLT1/3 and YEATS2/4) by methylating the amide of PFI-6 [1].
Cat. No.: HY-184342
Target:
Research Areas:
SYC-2863 is a CRBN-recruiting PROTAC degrader that selectively degrades ENL (MLLT1), with an ENL DC50 of 45 nM in MV4;11 cells. SYC-2863 inhibits the proliferation of MLL-rearranged leukemia and multiple myeloma cells. After degrading intracellular ENL, SYC-2863 dose-dependently downregulates the transcription levels of MYC and its downstream target genes, blocking the MYC-mediated malignant proliferation pathway. SYC-2863 can be used in studies related to MLL-rearranged leukemia and multiple myeloma [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
